Heart Failure – an Evolving Landscape: 2021: A Turning Point in Heart Failure?

Published: 23 November 2021

  • Views:

    Views Icon 687
  • Likes:

    Heart Icon 7

Overview

Full programme

  • Views:

    Views Icon 687
  • Likes:

    Heart Icon 7
Part 4

of 4

Are we moving towards individualising GDMT in HF?

Andrew JS Coats, Biykem Bozkurt, Ileana L Piña, Clyde W Yancy

Overview

In this third and final roundtable of the series, Prof Andrew Coats is joined by Dr Clyde Yancy, Dr Biykem Bozkurt and Dr Ileana Piña for their insight on the recent and forthcoming guideline recommendations and the premise of moving towards individualised care in HF. The experts recap of where we are in 2021, bringing the audience up to speed on an exciting and busy couple of years for foundational therapy. In the second discussion, the faculty summarise recent European HF guidelines and posit how the forthcoming American guidelines are set to change. The dialogue also provides insight into how SGLT-2 inhibitors may be positioned in future guidance.
 

In the final session, the faculty look at how foundational treatment impacts specific populations across the EF spectrum and discuss how genotyping and deep phenotyping are set to impact future treatment strategies. The faculty end the discussion by considering the performance of specific patient populations, drawing on results from EMPULSE, EMPEROR-PRESERVED, EMPEROR-REDUCED and DAPA-HF.

Supported by the Boehringer Ingelheim & Lilly Alliance

Learning Objectives

  • Understand recent changes to (ESC / AHA / ACC) HF guidelines
  • Understand the latest data and meta data in the HF space (both for HFrEF and HFpEF)
  • Understand the appropriate treatment algorithms for HF patients
  • Understand appropriate utilisation of SGLT2s in the HFpEF and HFrEF spaces

Target Audience

  • HF specialists
  • General cardiologists
  • GPs

More from this programme

Faculty biographies